

Cell Counting Market to Reach \$16.3 Billion, Globally, by 2032 at 7.7% CAGR | PerkinElmer, Aligned Genetics, ChemoMetec

PORTLAND, IL, UNITED STATES, March 17, 2025 /EINPresswire.com/ -- According to the report, the global [cell counting industry](#) generated \$7.7 billion in 2022, and is anticipated to generate \$16.3 billion by 2032, witnessing a CAGR of 7.7% from 2023 to 2032.

Request Sample of the Report on Cell Counting Market Forecast 2032-
<https://www.alliedmarketresearch.com/request-sample/848>

Technological advancements in cell counting instruments, rise in incidences of chronic and infectious diseases, and increase in funding for cell-based research are the factors driving the growth of the global cell counting market. However, high cost and maintenance of cell counting instruments are expected to restrict the market growth. Moreover, growth in opportunities in emerging markets presents new opportunities in the coming years.

Economic Downturn Analysis: Impact of Recession in 2023 on the Cell Counting Market

Recessions typically lead to budget constraints in the healthcare sector as governments, hospitals and healthcare providers face financial pressure. There is an increased focus on cost containment and efficient resource allocation.

Recessions often result in budget cuts, impacting research funding from both public and private sectors. Reduced funding affects academic institutions, research centers, and biotechnology companies engaged in life sciences research.

However, despite budget constraints, the significance of healthcare research remains pivotal even during challenging economic times. Diseases and health concerns persist, fostering sustained demand for cell counting technologies in critical areas such as disease research, diagnostics and drug development.

Have a Question? Connect to our Analyst- <https://www.alliedmarketresearch.com/connect-to-analyst/848>

The accessories and consumables segment to maintain its leadership status throughout the forecast period

Based on product type, the accessories and consumables segment held the largest market share in 2022, less than three-fifths of the global cell counting market revenue and is estimated to

maintain its leadership status throughout the forecast period. This is attributed to continuous usage and necessity of the consumables such as reagents, counting chambers, calibration standards, and sensor cassettes, in routine laboratory operations and diagnostics, thereby driving the growth of the segment.

However, the instruments segment is projected to attain the fastest CAGR of 8.5% from 2023 to 2032. This is attributed to various technological advancements leading to the development of more sophisticated and automated cell counting instruments, enhancing accuracy, speed and throughput. In addition, increased adoption of automated cell counting systems in clinical diagnostics and research facilities, driven by the need for high-throughput and precise analyses, fuels the growth of the segment.

The research applications segment to maintain its leadership status throughout the forecast period

Based on application, the cell biology segment held the largest market share in 2022, accounting less than half of the global cell counting market and is estimated to maintain its leadership status throughout the forecast period, owing to rise in fundings for research and development leading to adoption of cell counting systems. In addition, extensive utilization of cell counting technologies in various academic and industrial research to study biological sciences, drug development, and various diseases is expected to fuel the segment growth.

However, the clinical and diagnostics applications segment is projected to attain the fastest CAGR of 8.5% from 2023 to 2032, owing to growth in prevalence of chronic diseases which necessitates accurate diagnostic tools, escalating the adoption of cell counting systems for disease assessment and management.

The pharmaceutical and biotechnological companies' laboratories segment to maintain its lead position during the forecast period

Based on end user, the pharmaceutical and biotechnological companies segment accounted for the largest share in 2022, contributing to more than two-fifths of the global cell counting market revenue, and is projected to maintain its lead position during the forecast period. This is attributed to the significant investment in research, driving the demand for precise cell counting technologies, increasing adoption of cell counting for quality control, ensuring the efficacy and safety of pharmaceutical products and biotechnological advancements. In addition, continuous innovation in pharmaceuticals and biotechnology drives the demand for precise cell counting technologies, crucial for drug development and research.

However, the hospitals and diagnostic laboratories segment is expected to witness the fastest CAGR of 8.4% from 2023 to 2032, owing to rise in prevalence of chronic diseases which necessitates accurate diagnostics, elevating the adoption of cell counting systems for disease assessment and management. In addition, advancements in healthcare infrastructure and the

expansion of diagnostic capabilities in hospitals and laboratories augment the adoption of sophisticated cell counting instruments for improved patient care, thereby driving the segment growth.

For Procurement Information- <https://www.alliedmarketresearch.com/purchase-enquiry/848>

North America to maintain its dominance by 2032

Based on region, North America held the largest market share in terms of revenue in 2022, accounting for more than two-fifths of the global cell counting market revenue and is likely to dominate the market during the forecast period, owing to advanced healthcare infrastructure, substantial investments in research and development, presence of major key players offering advanced cell counters, and the presence of leading biotechnology and pharmaceutical companies. In addition, increase in emphasis of the region on precision medicine, coupled with rise in healthcare expenditure, fuels the need for accurate diagnostics and personalized treatments, further propelling the utilization of cell counting technologies. Furthermore, continuous technological advancements, including the integration of automation and digital health solutions into cell counting systems contribute to the growth of the market.

However, the Asia-Pacific region is expected to witness the fastest CAGR of 9.0% from 2023 to 2032. This is attributed to rise in population, increase in healthcare spending and rapid technological advancements that contribute significantly to the market growth. Rise in prevalence of chronic diseases and infectious conditions in countries such as China, India, and Southeast Asian countries fuels the demand for precise diagnostics and advanced medical technologies. The expansion of biopharmaceutical sector in Asia-Pacific, coupled with a focus on innovative therapies and drug development, propels the adoption of cell counting technologies.

Leading Market Players:

Danaher Corporation
Agilent Technologies, Inc.
Merck KGaA
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
PerkinElmer, Inc.
Aligned Genetics
ChemoMetec
NanoEntek
DeNovix Inc.

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of

Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa

Allied Market Research

+ 1800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/794546658>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.